HC Wainwright Analysts Boost Earnings Estimates for BriaCell Therapeutics Corp. (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Research analysts at HC Wainwright lifted their FY2024 earnings estimates for BriaCell Therapeutics in a report released on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.80) for the year, up from their previous estimate of ($1.39). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.52) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.12) EPS.

BriaCell Therapeutics Stock Performance

BCTX opened at $0.63 on Monday. The company’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $1.47. BriaCell Therapeutics has a 1 year low of $0.46 and a 1 year high of $6.36. The stock has a market capitalization of $11.56 million, a PE ratio of -0.51 and a beta of 1.31.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc raised its holdings in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 7.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,044 shares of the company’s stock after buying an additional 6,329 shares during the period. K.J. Harrison & Partners Inc owned about 0.54% of BriaCell Therapeutics worth $249,000 at the end of the most recent reporting period. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.